Fabienne Lecorvaisier - Sanofi ADR Director
| SNY Stock | USD 50.03 0.80 1.63% |
Director
Ms. Fabienne Lecorvaisier has served as Independent Director of Sanofi S.A. since May 2013. She was Member of the Audit Committee of the Company, and was appointed its Chairman as of May 2, 2018. She is a graduate of Ecole Nationale des Ponts et Chaussees. Since July 2017 she was Member of the Executive Committee and Deputy CEO in charge of Finance at Air Liquide. She began her career at Societe Generale and later held various positions at Barclays Bank and the Banque du Louvre. In 1993, she joined the Essilor Group as Development Director before being appointed Finance and Information Systems Director of Essilor America in 1996, then Chief Financial Officer of the Group in 2001 and Senior VicePresident Strategy and Acquisitions in 2007. In 2008, she was appointed VicePresident, Finance and Administration of the Air Liquide Group, and member of its Group Executive Committee. Ms. Lecorvaisier is currently also Chief Executive Officer and Chairwoman of Air Liquide Finance. since 2013.
| Age | 55 |
| Tenure | 11 years |
| Address | 46, avenue de la Grande Armée,, Paris, France, 75017 |
| Phone | 33 1 53 77 40 00 |
| Web | https://www.sanofi.com |
Sanofi ADR Management Efficiency
The company has Return on Asset of 0.0454 % which means that on every $100 spent on assets, it made $0.0454 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0727 %, implying that it generated $0.0727 on every 100 dollars invested. Sanofi ADR's management efficiency ratios could be used to measure how well Sanofi ADR manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.14 in 2024. Return On Capital Employed is likely to rise to 0.17 in 2024. At this time, Sanofi ADR's Non Currrent Assets Other are fairly stable compared to the past year. Intangible Assets is likely to rise to about 77.3 B in 2024, whereas Total Assets are likely to drop slightly above 88.2 B in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Vindi Banga | GlaxoSmithKline PLC ADR | N/A | |
| Patricia Russo | Merck Company | 68 | |
| Andreas Planta | Novartis AG ADR | 65 | |
| Frank Herringer | Amgen Inc | 74 | |
| John Madigan | Gilead Sciences | 77 | |
| Ronald Williams | Johnson Johnson | 71 | |
| Deryck Maughan | GlaxoSmithKline PLC ADR | 66 | |
| Shriti Vadera | AstraZeneca PLC ADR | 55 | |
| David Baltimore | Amgen Inc | 78 | |
| Thomas Glocer | Merck Company | 61 | |
| Craig Thompson | Merck Company | 64 | |
| John Cogan | Gilead Sciences | 70 | |
| Baroness Vadera | AstraZeneca PLC ADR | 52 | |
| Mary Beckerle | Johnson Johnson | 66 | |
| Eugene Washington | Johnson Johnson | 67 | |
| Graham Chipchase | AstraZeneca PLC ADR | 54 | |
| Paul Rothman | Merck Company | 63 | |
| Srikant Datar | Novartis AG ADR | 67 | |
| Carlos Represas | Merck Company | 72 | |
| Mary Coleman | Johnson Johnson | 70 | |
| Sherilyn McCoy | AstraZeneca PLC ADR | 60 | |
Management Performance
| Return On Equity | 0.0727 | ||||
| Return On Asset | 0.0454 |
Sanofi ADR Leadership Team
Elected by the shareholders, the Sanofi ADR's board of directors comprises two types of representatives: Sanofi ADR inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sanofi. The board's role is to monitor Sanofi ADR's management team and ensure that shareholders' interests are well served. Sanofi ADR's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sanofi ADR's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dominique Carouge, Executive Vice President - Head of Business Transformation Member of the Executive Committee | ||
| Emmanuel Babeau, Independent Director | ||
| Roy Papatheodorou, Executive Counsel | ||
| Pascale Witz, Executive Vice President - Global Divisions & Strategic Commercial Development, Member of the Executive Committee and the Global Leadership Team | ||
| Serge Weinberg, Chairman, Interim CEO, Chairman of Appointments and Governance Committee and Chairman of Strategy Committee | ||
| Dieter Weinand, Executive Vice President Member of the Executive Board | ||
| Sebastien Martel, Vice President - Investor Relations and Member of the Global Leadership Team | ||
| Eva SchaeferJansen, Head Relations | ||
| Fabienne Lecorvaisier, Director | ||
| George Grofik, Vice President of Investor Relations | ||
| Karen Linehan, Executive VP of Legal Affairs and General Counsel | ||
| Klaus Pohle, Independent Director | ||
| John Reed, President - Global Research & Development, Member of the Executive Committee | ||
| Bernard Charles, Independent Director | ||
| Natalie Bickford, Executive Officer | ||
| FranoisXavier Roger, Chief Officer | ||
| Melanie Lee, Independent Director | ||
| Madeleine Roach, Executive Operations | ||
| Pierre Chancel, Senior Marketing | ||
| Christophe Babule, Director | ||
| Bonnie Bassler, Director | ||
| Thomas Suedhof, Independent Director | ||
| Caroline Luscombe, Executive Vice President of Human Resources, Member of the Executive Committee | ||
| Laurent Attal, Director | ||
| JeanRene Fourtou, Independent Director | ||
| JeanBaptiste Chatillon, CFO, Executive Vice President Member of the Executive Committee | ||
| Josephine Fubara, Chief Care | ||
| Christian Mulliez, Director | ||
| Robert Castaigne, Independent Director | ||
| Laurent Gilhodes, Principal Accounting | ||
| Jerome Contamine, Executive Vice President - CFO, Member of the Executive Committee and Global Leadership Team | ||
| Uwe Bicker, Independent Director | ||
| Josep Catlla, Head Communications | ||
| Claudie Haignere, Independent Director | ||
| Olivier Brandicourt, CEO, Director and Member of Strategy Committee | ||
| Paul Hudson, CEO Director | ||
| Bruno Mnard, Chief officer | ||
| Suresh Kumar, Executive Vice President - External Affairs, Member of the Executive Committee and Global Leadership Team | ||
| Dante Beccaria, Global VP | ||
| Kathleen Tregoning, Executive Vice President External Affairs; Member of the Executive Committee | ||
| William Sibold, Executive Vice President Sanofi Genzyme; Member of the Executive Committee | ||
| Peter Guenter, Executive Vice President - Global Commercial Operations, Member of the Executive Committee and the Global Leadership Team | ||
| David Loew, Member of the Global LeaderShip Team, Senior Vice President - Commercial Operations Europe | ||
| Muzammil Mansuri, Executive Vice President Strategy & Business Development, Member of the Executive Committee and the Senior Leadership Team | ||
| Diane Souza, Independent Director | ||
| Carole Piwnica, Independent Director | ||
| Elias Zerhouni, President - Global Research & Development, Member of the Executive Committee and the Global Leadership Team | ||
| Ameet Nathwani, Executive Vice President Group Chief Medical Officer, Member of the Executive Committee | ||
| Philippe Luscan, Senior Vice President - Industrial Affairs, Member of the Executive Committee and the Global Leadership Team | ||
| Roberto Pucci, Senior Vice President - Human Resources, Member of the Executive Committee and the Global Leadership Team | ||
| DavidAlexandre Gros, Executive Vice President Chief Strategy Officer and Member of the Executive Committee | ||
| Olivier Charmeil, Senior Vice President - Vaccines, Member of the Executive Committee and Global Leadership Team | ||
| Igor Landau, Director | ||
| Patrick Kron, Independent Director | ||
| Stefan Oelrich, Executive Vice President - Diabetes & Cardiovascular, Member of the Executive Committee | ||
| Gerard Kemmel, Independent Director | ||
| SuetFern Lee, Independent Director | ||
| Carsten Hellmann, Executive Vice President - Animal Health and Member of the Global Leadership Team | ||
| David Meeker, Member of the Executive Board and Executive Vice President - Genzyme and Member of the Global Leadership Team | ||
| Alan Main, Executive Vice President Consumer Healthcare; Member of the Executive Committee | ||
| Suet Lee, Independent Director |
Sanofi Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sanofi ADR a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0727 | ||||
| Return On Asset | 0.0454 | ||||
| Profit Margin | 0.1 % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 71.49 B | ||||
| Shares Outstanding | 2.5 B | ||||
| Shares Owned By Institutions | 10.01 % | ||||
| Number Of Shares Shorted | 3.24 M | ||||
| Price To Earning | 7.78 X | ||||
| Price To Book | 1.44 X |
Currently Active Assets on Macroaxis
When determining whether Sanofi ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sanofi ADR's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sanofi Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sanofi Adr Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sanofi ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Sanofi Stock please use our How to Invest in Sanofi ADR guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Complementary Tools for Sanofi Stock analysis
When running Sanofi ADR's price analysis, check to measure Sanofi ADR's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi ADR is operating at the current time. Most of Sanofi ADR's value examination focuses on studying past and present price action to predict the probability of Sanofi ADR's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi ADR's price. Additionally, you may evaluate how the addition of Sanofi ADR to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |
Is Sanofi ADR's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sanofi ADR. If investors know Sanofi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sanofi ADR listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.43) | Earnings Share 1.93 | Revenue Per Share 18.492 | Quarterly Revenue Growth 0.023 | Return On Assets 0.0454 |
The market value of Sanofi ADR is measured differently than its book value, which is the value of Sanofi that is recorded on the company's balance sheet. Investors also form their own opinion of Sanofi ADR's value that differs from its market value or its book value, called intrinsic value, which is Sanofi ADR's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sanofi ADR's market value can be influenced by many factors that don't directly affect Sanofi ADR's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sanofi ADR's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sanofi ADR is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sanofi ADR's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.